Search research articles
Contact Us
Filters
Showing results (61-70 of 107) with videos related to
Page
of 11
Sort By:
Gynecologic Oncology
|
October 11, 2022
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26)
Domenica Lorusso, Sandro Pignata, Stefano Tamberi, et al.
Diagnostics (Basel, Switzerland)
|
April 14, 2026
Corneal Toxicity of Mirvetuximab Soravtansine: Multimodal Imaging Features and Implications for Ophthalmologic Management
Francesco De Dominicis, Andrea Giudiceandrea, Martina Cocuzza, et al.
Journal of Gynecologic Oncology
|
March 18, 2024
Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey
Innocenza Palaia, Giuseppe Caruso, Violante Di Donato, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 5, 2021
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Lucia Musacchio, Vanda Salutari, Sandro Pignata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 9, 2023
Survival outcomes in patients with <i>BRCA</i> mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors
Lucia Musacchio, Serena Boccia, Claudia Marchetti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 20, 2017
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project
Marilena Di Napoli, Chiara Della Pepa, Laura Arenare, et al.
Frontiers in Oncology
|
May 15, 2026
Clinical and molecular heterogeneity in advanced-stage <i>POLE</i>-mutated endometrial carcinoma: a focus on aggressive subsets and co-mutations
Nicolo Cavasin, Sami Kilzie, Mattia Vinci, et al.
Gynecologic Oncology
|
January 10, 2020
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study
Molly Brewer, Roberto Angioli, Giovani Scambia, et al.
Gynecologic Oncology
|
March 25, 2023
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial
Lucia Musacchio, Margherita Turinetto, Laura Arenare, et al.
Oncology
|
June 20, 2014
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9)
Francesca Esposito, Sabrina Chiara Cecere, Francescapaola Magazzino, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 107) with videos related to
Sort By:
Page
of 11
Gynecologic Oncology
|
October 11, 2022
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26)
Domenica Lorusso, Sandro Pignata, Stefano Tamberi, et al.
Diagnostics (Basel, Switzerland)
|
April 14, 2026
Corneal Toxicity of Mirvetuximab Soravtansine: Multimodal Imaging Features and Implications for Ophthalmologic Management
Francesco De Dominicis, Andrea Giudiceandrea, Martina Cocuzza, et al.
Journal of Gynecologic Oncology
|
March 18, 2024
Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey
Innocenza Palaia, Giuseppe Caruso, Violante Di Donato, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 5, 2021
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Lucia Musacchio, Vanda Salutari, Sandro Pignata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 9, 2023
Survival outcomes in patients with <i>BRCA</i> mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors
Lucia Musacchio, Serena Boccia, Claudia Marchetti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 20, 2017
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project
Marilena Di Napoli, Chiara Della Pepa, Laura Arenare, et al.
Frontiers in Oncology
|
May 15, 2026
Clinical and molecular heterogeneity in advanced-stage <i>POLE</i>-mutated endometrial carcinoma: a focus on aggressive subsets and co-mutations
Nicolo Cavasin, Sami Kilzie, Mattia Vinci, et al.
Gynecologic Oncology
|
January 10, 2020
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study
Molly Brewer, Roberto Angioli, Giovani Scambia, et al.
Gynecologic Oncology
|
March 25, 2023
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial
Lucia Musacchio, Margherita Turinetto, Laura Arenare, et al.
Oncology
|
June 20, 2014
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9)
Francesca Esposito, Sabrina Chiara Cecere, Francescapaola Magazzino, et al.
Page
of 11